Measles and rubella virus vaccine - Biological E Limited
Latest Information Update: 01 Sep 2016
At a glance
- Originator Biological E Limited
- Class Measles vaccines; Rubella vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Measles; Rubella
Most Recent Events
- 30 Aug 2016 Biological E Limited plans a phase II/III trial for Measles and Rubella (In volunteers, In infants, Prevention) (CTRI2016-07-007109)